The HMG20A Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 liver adenocarcinoma cell line, featuring targeted disruption of the HMG20A gene. This product provides a heterogeneous pool of cells harboring loss-of-function mutations in HMG20A, generated through CRISPR/Cas9-mediated gene disruption. It serves as a robust tool for investigating HMG20A-dependent regulatory mechanisms in a liver sinusoidal endothelial-like context, without implying clonal isolation or specific editing outcomes. The polyclonal format preserves phenotypic diversity while enabling functional loss-of-function studies.
The SK-HEP-1 host cell line originates from the ascites of a patient with liver adenocarcinoma and exhibits endothelial characteristics, making it a widely used model for liver sinusoidal endothelial cell (LSEC) functions. These cells endogenously express markers associated with filtration, endocytosis, and leukocyte adhesion, faithfully recapitulating key aspects of LSEC biology. Their dual epithelial-endothelial phenotype offers a unique platform to study tumor microenvironment interactions and hepatic vascular processes, providing a physiologically relevant background for interrogating the role of chromatin regulators like HMG20A.
HMG20A encodes a transcription factor and chromatin remodeling protein that functions as a core component of the SWI/SNF (BAF) complex. It acts as a transcriptional co-repressor within the REST/NRSF complex, associating with CoREST, HDAC1, and HDAC2 to silence neuronal genes such as SYN1 and BDNF. Additionally, HMG20A interacts with SMARCA4 (BRG1) and SMARCB1 (BAF47) to modulate chromatin structure. Upstream, it is activated by TGF-beta signaling and REST/NRSF. Downstream, it represses CDKN1A (p21) and CDH1 (E-cadherin), thereby regulating cell cycle progression and genomic stability. Its knockout abrogates these repressive and remodeling activities, potentially altering TGF-beta-mediated SMAD7 expression and downstream cellular responses.
In the SK-HEP-1 background, disruption of HMG20A is predicted to compromise REST complex-mediated gene silencing and SWI/SNF-dependent chromatin dynamics. Given the cell line’s endothelial properties, this knockout model enables exploration of HMG20A’s contribution to LSEC-specific processes such as barrier integrity, adhesion molecule expression, and angiogenic responses. The interplay between HMG20A loss and TGF-beta signaling may further affect cell proliferation, migration, and apoptosis, offering insights into hepatocellular carcinoma progression and vascular biology. Thus, these cells provide a relevant system to dissect the molecular underpinnings of HMG20A in hepatic and endothelial contexts.
Typical applications include confirmatory western blotting for HMG20A knockout, RT-qPCR to assess derepression of neuronal genes, and RNA-seq for global transcriptomic profiling. Functional assays such as MTT proliferation, Transwell migration, Annexin V apoptosis, and SMAD phosphorylation analysis can delineate HMG20A-dependent signaling. Endothelial tube formation assays further extend utility to angiogenesis studies. These cells are suitable for elucidating HMG20A’s role in REST complex-mediated repression, chromatin remodeling, TGF-beta pathway modulation, and drug target validation in liver cancer and endothelial biology. For further technical support and inquiries, please contact Ascent Research.
